Attributes | Values |
---|
rdf:type
| |
rdfs:seeAlso
| |
Description
| - Ixazomib citrate, produced and patented by Millennium Pharmaceuticals, is one of the %22new-generation%22 proteasome inhibitors following the success story of the first-in-class proteasome inhibitor bortezomib. Today, bortezomib is approved for multiple myeloma and mantle cell lymphoma, but has failed in clinical trials in patients with solid tumors. According to available preclinical data, ixazomib citrate may be more active in solid tumors. It also appears to be better tolerated by patients, as the most serious adverse event for bortezomib, neuropathy, has not yet been observed in clinical trials with ixazomib citrate. Ixazomib citrate can be administered both intravenously and orally.
- Ixazomib citrate, produced and patented by Millennium Pharmaceuticals, is one of the %22new-generation%22 proteasome inhibitors following the success story of the first-in-class proteasome inhibitor bortezomib. Today, bortezomib is approved for multiple myeloma and mantle cell lymphoma, but has failed in clinical trials in patients with solid tumors. According to available preclinical data, ixazomib citrate may be more active in solid tumors. It also appears to be better tolerated by patients, as the most serious adverse event for bortezomib, neuropathy, has not yet been observed in clinical trials with ixazomib citrate. Ixazomib citrate can be administered both intravenously and orally. (en)
|
Title
| - Ixazomib Citrate Proteasome Inhibitor Oncolytic
- Ixazomib Citrate Proteasome Inhibitor Oncolytic (en)
|
skos:prefLabel
| - Ixazomib Citrate Proteasome Inhibitor Oncolytic
- Ixazomib Citrate Proteasome Inhibitor Oncolytic (en)
|
skos:notation
| - RIV/61989592:15310/12:33141659!RIV13-MSM-15310___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15310/12:33141659
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - profile; resistance; MLN9708; colorectal-cancer; antitumor-activity; peripheral neuropathy; multiple-myeloma; phase-II; single-agent bortezomib; metastatic breast-cancer (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - ES - Španělské království
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...vavai/riv/projekt
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://bibframe.org/vocab/doi
| - 10.1358/dof.2012.37.8.1835040
|
http://localhost/t...ganizacniJednotka
| |